From the 1Department of Pediatrics, Mousavi Hospital, Zanjan University of Medical Sciences, Zanjan, Iran; 2Department of Pediatrics, Beheshti Hospital, Langrood, Iran; 3Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; 4Molecular Immunology Research Center; and Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
World Allergy Organ J. 2010 Oct;3(10):250-2. doi: 10.1097/WOX.0b013e3181f68d92.
Asthma is a common chronic disease. Beclomethasone dipropionate (BDP) and Fluticasone propionate (FP) are 2 inhaled corticosteroids that frequently be used in treatment of patients with asthma. In this study, the effectiveness of BDP and FP in management of asthmatic children was investigated. In this trial, 50 children with moderate persistent asthma were randomly selected to receive either BDP 600 μg or FP 500 μg for 3 months. Pulmonary function tests were measured in both groups at the beginning of study and monthly after treatment. Daily and night symptoms and consistency of drugs were also measured. There was significantly better FEV1 in patients receiving FP compared with the BDP group (P < 0.01). There was also statistically significant difference in patients receiving FP compared with BDP group in increment of FVC, FEV1/FVC, FEF25-75 (P < 0.005). Night symptoms were significantly improved in the FP group from the first month (P = 0.001), while improvement of daily symptoms in this group compared with the BDP group was found from the second month (P = 0.001). Although symptoms and pulmonary function tests results were improved in both groups receiving either FP or BDP, this study suggested that FP was more effective than BDP in controlling moderate asthma in children.
哮喘是一种常见的慢性疾病。倍氯米松双丙酸酯（BDP）和丙酸氟替卡松（FP）是两种常用于治疗哮喘患者的吸入性皮质类固醇。本研究旨在探讨 BDP 和 FP 治疗哮喘儿童的疗效。本试验中，随机选择 50 例中度持续性哮喘患儿，分别给予 BDP 600μg 或 FP 500μg，治疗 3 个月。两组患儿在研究开始时和治疗后每月进行肺功能检查，同时还评估每日和夜间症状及药物使用的一致性。与 BDP 组相比，FP 组的 FEV1 明显改善（P<0.01）。与 BDP 组相比，FP 组的 FVC、FEV1/FVC、FEF25-75 也有统计学差异（P<0.005）。FP 组的夜间症状从第一个月开始明显改善（P=0.001），而与 BDP 组相比，该组的日间症状改善从第二个月开始（P=0.001）。尽管两组患儿在接受 FP 或 BDP 治疗后症状和肺功能检查结果均有所改善，但本研究表明 FP 比 BDP 更能有效控制儿童中度哮喘。
